BioSpace News Archive

The novel system, which has been shown to significantly reduce the risk of stroke in the first three days after TAVR by more than 60 percent, has been adopted by 50 U.S. centers as part of its controlled rollout.

The solution integrates the novel extraction chemistry on the Hamilton Microlab STAR liquid handling platform to provide high through-put solution for applications such as biorepositories, genomics research and pharmacogenomics that require substantial amounts of DNA to be extracted from large-volume samples.

Novartis receives funding from Bill & Melinda Gates Foundation for further development of Novartis drug candidate KDU731 for the treatment of cryptosporidiosis.

Accordingly, this debt has now been removed from the Company’s balance sheet.

Pursuant to the agreement, Novoheart will test Sumocor’s candidate therapeutics in three phases on Novoheart’s MyHeart Platform of human bioengineered heart constructs.

The Company will host a conference call and live audio webcast at 4:30 p.m. ET that day to discuss the results and provide a company update.

Imaging3 prepares to revisit a 510K submission.

The sale of the notes is expected to close on February 16, 2018, subject to customary closing conditions.

An accompanying conference call will be hosted by Dan Myers, Chief Executive Officer and Rick Eiswirth, President and Chief Financial Officer to discuss the results.

RegeneRx, through its U.S joint venture, ReGenTree LLC, completed patient enrollment and treatment in its second Phase 3 clinical trial in approximately 600 patients with dry eye syndrome, reported positive clinical results, and has scheduled a meeting with the U.S. FDA in April 2018.